Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preventing Osteoporosis Using Denosumab (PROUD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02753283
Recruitment Status : Suspended (IRB recruitment suspension due to COVID-19 related research restrictions.)
First Posted : April 27, 2016
Last Update Posted : April 20, 2020
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Susan L. Greenspan, University of Pittsburgh

Brief Summary:
The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.

Condition or disease Intervention/treatment Phase
Osteoporosis, Postmenopausal Osteoporosis Osteoporotic Fractures Drug: denosumab Drug: Placebo Dietary Supplement: Calcium and Vitamin D Drug: Zoledronic Acid Phase 4

Detailed Description:

Objective:

The long term goal is to improve health, well-being and quality of life in the frail long-term care (LTC) elderly population by reducing fractures. The short term goal is to demonstrate efficacy of the non-bisphosphonate denosumab to improve bone mineral density (BMD), a necessary (but not sufficient) pre-condition of a large fracture reduction trial. The investigators propose to conduct a 2-year, randomized, double-blind, calcium-vitamin D controlled trial to test the efficacy and predictability of the antiresorptive RANK ligand inhibitor, denosumab (60 mg), among a cohort of 212 institutionalized, under-served, frail men and women ≥65 years old in LTC.

Specific Aims:

Aim 1: To evaluate efficacy of denosumab in improving/maintaining bone mineral density. The investigators will measure conventional hip and spine bone mineral density (BMD).

Primary Hypothesis: After 2 years, women and men on denosumab will have greater hip and spine BMD increases.

Zoledronic Acid Infusion Safety Treatment and Follow-up Extension:

After the trial was started, case reports suggested a potential increase in fracture risk with disuse. A post hoc analysis that combined the pivotal denosumab trial and extension trial data suggested there was an increase in multiple vertebral fractures when patients discontinued therapy. Following discontinuation of denosumab/placebo, all patients will be offered treatment with 1 dose of intravenous zoledronic acid 5 mg. For those consenting to receive end of study treatment, the zoledronic acid will be given at month 27 for an individual patient.

Zoledronic Acid Safety Infusion Extension Specific Aims:

Aim 1: To evaluate maintenance of bone mineral density (BMD). Zoledronic acid will be administered intravenously at 9 months post-denosumab (month 27) and assess BMD by DXA at months 33 and 39 (6 months and 12 months after zoledronic acid infusion).

Primary Hypothesis: Zoledronic acid will prevent BMD loss at the spine and hip following denosumab discontinuation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 212 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Sustaining Skeletal Health in Frail Elderly
Study Start Date : June 2016
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Arm Intervention/treatment
Experimental: Denosumab, then Zoledronic Acid
Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
Drug: denosumab
Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
Other Name: Prolia

Dietary Supplement: Calcium and Vitamin D
Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Drug: Zoledronic Acid
One time safety treatment dose: 5 mg infusion
Other Name: Reclast

Placebo Comparator: Placebo Group, then Zoledronic Acid
Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
Drug: Placebo
Semi-annual saline injection

Dietary Supplement: Calcium and Vitamin D
Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Drug: Zoledronic Acid
One time safety treatment dose: 5 mg infusion
Other Name: Reclast




Primary Outcome Measures :
  1. Bone density of the total hip [ Time Frame: 24 months ]
    Bone Mineral Density (BMD) of the total hip at 24 months as assessed by dual-energy x-ray absorptiometry (DXA)

  2. Bone density of the spine [ Time Frame: 24 months ]
    Bone Mineral Density (BMD) of the spine at 24 months as assessed by dual-energy x-ray absorptiometry (DXA)

  3. Extension - Zoledronic Acid Infusion Safety Treatment: Bone density of the total hip [ Time Frame: 33 months ]
    Bone Mineral Density (BMD) of the total hip at 33 months as assessed by dual-energy x-ray absorptiometry (DXA)

  4. Extension - Zoledronic Acid Infusion Safety Treatment: Bone density of the total hip [ Time Frame: 39 months ]
    Bone Mineral Density (BMD) of the total hip at 39 months as assessed by dual-energy x-ray absorptiometry (DXA)

  5. Extension - Zoledronic Acid Infusion Safety Treatment: Bone density of the spine [ Time Frame: 33 months ]
    Bone Mineral Density (BMD) of the spine at 33 months as assessed by dual-energy x-ray absorptiometry (DXA)

  6. Extension - Zoledronic Acid Infusion Safety Treatment: Bone density of the spine [ Time Frame: 39 months ]
    Bone Mineral Density (BMD) of the spine at 39 months as assessed by dual-energy x-ray absorptiometry (DXA)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Ambulatory male and female residents with osteoporosis or low bone mass (at risk for fracture) ages 65 and older will be considered if:

  • Reside in long-term care institution (nursing home or assisted living facility); and
  • HaveOsteoporosis: (1) by bone density [spine, hip or forearm Bone Mineral Density (BMD) T-score ≤ -2.5]; (2) A previous adult fragility fracture of the spine or hip; or (3) Would be treated based on FRAX® and the National Osteoporosis Foundation (NOF) treatment thresholds of a 10 year risk of ≥ 20% for a major fracture or ≥ 3% for hip fracture suing femoral neck BMD.

Exclusion Criteria:

  • Institutionalized residents with subacute illnesses who are not expected to survive or who will be discharged in < 2 years.
  • Non-ambulatory residents (those who cannot stand and pivot with assistance in order to transfer to the DXA table).
  • Those currently on therapy (including bisphosphonate, denosumab, or teriparatide) or who have been on a bisphosphonate for > 1year during the previous 2 years because some bisphosphonates are long acting.
  • Those with a history of hypocalcemia or contraindication for treatment. We will screen for these conditions by detailed history, chart review, and baseline laboratory analyses.
  • Those with vitamin D levels < 25ng/mL will be treated with vitamin D 50,000 IU/wk for 8 weeks; they will be enrolled if the follow-up vitamin D level is 25 ng/mL or more (if after 2 rounds of vitamin D repletion their vitamin D level is not at least 25 ng/mL, they will not be eligible to be randomized into the study).
  • Those on dialysis or with stage 5 chronic kidney disease (eGFR<15ml/min) will be excluded at screening.
  • Those requiring tooth extraction or oral surgery will not be enrolled until cleared by a dentist.
  • Patients will be allowed to continue on glucocorticoids and anticonvulsants because their use is common in this population.
  • Those on glucocorticoids and anticonvulsants will be allowed to continue in the study because their use is common in this population.
  • Those on hormone replacement therapy (HRT), raloxifene, or prescribed protective hip pads by their Primary Care Physician (PCP) will be allowed to participate and continue on these therapies.
  • We will suggest that participants stop long-term calcitonin as it has been discontinued in Europe due to cancer concerns.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02753283


Locations
Layout table for location information
United States, Pennsylvania
UPMC Senior Communities
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Susan L. Greenspan
National Institutes of Health (NIH)
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Susan L Greenspan, MD University of Pittsburgh
Layout table for additonal information
Responsible Party: Susan L. Greenspan, Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02753283    
Other Study ID Numbers: STUDY19050268
1R01AG052123-01 ( U.S. NIH Grant/Contract )
First Posted: April 27, 2016    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Susan L. Greenspan, University of Pittsburgh:
Bone loss
Frail Geriatric Patients
Nursing Home Patients
Long-term Care Patients
Osteoporosis
Osteoporotic Fractures
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis
Osteoporosis, Postmenopausal
Osteoporotic Fractures
Fractures, Bone
Wounds and Injuries
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Vitamin D
Zoledronic Acid
Denosumab
Calcium
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents